STIFEL 2026 HEALTHCARE CONFERENCE - 4D MOLECULAR THERAPEUTICS INC

Explicit Guidance:

• No specific financial guidance (revenue, earnings, margins, capex, opex, cash flow) provided.
• Cash Runway: Expected to extend into the second half of 2028.
• Clinical Timeline:
  • Top-line readout for Forefront I (Phase 3) scheduled for Q2 2027.
  • Top-line readout for Forefront II (Phase 3) scheduled for H2 2027.
• Pricing: No specific pricing guidance; management notes the product will not be priced at a single bolus anti-VEGF level and will be priced higher to reflect value capture over a multi-year window.

Business-Segment Outlook:

• Lead Program (4D150): Primary focus remains on 4D150 (gene therapy for wet AMD); other development programs are secondary.
• Commercial Strategy: Positioned as a "backbone therapy" intended for 24/7 continuous disease control, aiming for potential lifelong treatment with a single intravitreal injection.
• Target Product Profile (TPP): Aims to provide a shift from episodic bolus injections to a model where patients may be injection-free for life; targets recently diagnosed and treatment-naive populations.
• Reimbursement Model: Anticipated to utilize the "buy-and-bill" model familiar to retina clinics, where providers purchase the medicine upfront for administration.

Market and Competitive Outlook:

• Market Size: Wet AMD identified as a $16 billion category, growing due to an aging population and innovative therapies.
• Competitive Landscape:
  • Regenexx: Viewed as a proof-of-concept; differentiation lies in 4DMT's intravitreal (clinic-based) delivery versus Regenex's subretinal (surgical/operating room) approach.
  • Adverum/Lilly: Differentiated by 4DMT's low-dose approach and tissue-specific R100 vector, contrasting with Adverum's high-dose strategy which carries potential safety/inflammation concerns.
• Adoption Drivers: Management expects robust commercial adoption driven by physicians, patients, and payers; physicians survey indicate 40% of clinics are at capacity, suggesting potential to free up capacity by reducing visit frequency.
• Paradigm Shift: Management projects 4D150 could become the treatment of choice for the majority of wet AMD patients, rather than a niche therapy for a small minority.

Macro / Industry Outlook:

• Treatment Paradigm Evolution: Industry moving from incremental durability gains (e.g., 10–14 days extension) toward continuous disease control backbones.
• Economic Dynamics: While current providers are paid to inject, the economic model may shift to capture higher upfront value for long-acting therapies; real-world data suggests 60% of patients drop off treatment within five years, creating a "value loss" opportunity for 4DMT.
• Regulatory Environment: FDA guidance requires vision benefits in treatment-naive populations; trials have received RMAD (FDA) and PRIME (EMA) designations.

Strategic Initiatives:

• Phase 3 Trials (Forefront I & II): Fully enrolled global trials designed for global approval (FDA/EMA/PMDA).
  • Design Optimization: Capped anatomical entry criteria (500 microns) and required 15% CST reduction or fluid resolution to reduce variability and protect vision.
  • Safety Protocol: Implementation of a 20-week prophylactic steroid regimen (Durazol) to manage inflammation; management cites no patient hesitancy observed.
• Investor Relations: Focus on demonstrating data confirming "continuous control gap" closure and paradigm-shifting treatment burden reduction (potentially 80–90% reduction in supplemental injections).

Risks and Headwinds to Outlook:

• Safety Concerns: Potential for inflammation and safety events associated with gene therapy, though 4DMT attributes mitigation to low-dose, tissue-specific delivery.
• Clinical Readout: Binary risk tied to the Q2 and H2 2027 top-line data; failure to demonstrate non-inferiority in vision at week 52 would derail the pipeline.
• Commercial Adoption: Risk that physicians or payers may resist the shift from a high-volume injection model to a low-frequency, high-ticket model.
• Rescue Rates: Management declined to provide specific numbers for retreatment/rescue rates in the trial, noting variability based on patient severity.

Management Tone on the Future:

• Confidence Level: High confidence in the "paradigm-shifting" potential of 4D150; describes the approach as "unique" and "best in class."
• Differentiation: Emphasizes that unlike other gene therapies seeking incremental gains, 4DMT targets continuous disease control matching the chronic nature of wet AMD.
• Patient Alignment: Notes overwhelmingly positive patient receptivity to the potential of a single injection and the reduction of anxiety associated with chronic treatment.
• Hedges: Cautioned against specific numerical predictions on retreatment rates and pricing, citing the complexity of the market and binary nature of clinical outcomes.

Miscellaneous:

• Vector Technology: Proprietary R100 capsid allows for low-dose intravitreal delivery with minimal toxicity and inflammation.
• Payload: Utilizes aflibercept (Ilea), a molecule dosed in over 64 million eyes, combined with gene therapy for lifelong expression.
• Investor Day Reference: Management referenced recent investor day communications regarding patient interest and commercial potential.